Forte Biosciences (FBRX) Cash from Investing Activities Growth (1y) (2017 - 2025)
Forte Biosciences (FBRX) Cash from Investing Activities Growth (1y) (2017 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 62.68% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -674.01% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -166.24% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Forte Biosciences | 1.37 Bn | 1.31 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 604,916.67% |
| Dec 31, 2024 | -224,818.75% |
| Sep 30, 2020 | 99.98% |
| Jun 30, 2020 | -2,150.99% |
| Mar 31, 2020 | 108.66% |
| Dec 31, 2019 | -111.77% |
| Sep 30, 2019 | -177.25% |
| Jun 30, 2019 | -151.13% |
| Mar 31, 2019 | 266.54% |
| Dec 31, 2018 | 102.66% |
| Sep 30, 2018 | -127.45% |
| Jun 30, 2018 | 107.45% |
| Mar 31, 2018 | -197.08% |
| Dec 31, 2017 | -515.28% |
| Sep 30, 2017 | 17.72% |
| Jun 30, 2017 | -228.65% |
| Mar 31, 2017 | 25.16% |